Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1515926 | 0.90 | LMNA (0.55) | ALOX5HDAC4HDAC6TSHRALDH1A1 | |
| SCHEMBL2353230 | 0.86 | ALOX5 (0.76) | ALOX5NPC1RAB9ALTB4RLTB4R2 | |
| SCHEMBL1515761 | 0.85 | AOC3 (0.54) | LTB4RLTB4R2 | |
| SCHEMBL4952728 | 0.85 | FFAR1 (0.58) | ALOX5HDAC4HDAC6LTB4RLTB4R2 | |
| SCHEMBL9903521 | 0.84 | RAB9A (0.45) | ALOX5CES2CES1AKR1B1NPC1 | |
| SCHEMBL8064820 | 0.83 | HDAC4 (0.49) | ALOX5NPC1RAB9AHDAC4HDAC6 | |
| SCHEMBL13226836 | 0.83 | HDAC4 (0.49) | ALOX5HDAC4HDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL8371453 | 0.83 | HDAC4 (0.49) | ALOX5HDAC4HDAC6LTB4RLTB4R2 | |
| SCHEMBL1058423 | 0.82 | CTBP2 (0.50) | NPC1RAB9ALTB4RLTB4R2ALDH1A1 | |
| SCHEMBL12570225 | 0.82 | NPC1 (0.51) | NPC1RAB9AHDAC6ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2025262192-A1 | QUINAZOLINE DERIVATIVES SUITABLE FOR USE AS WERNER SYNDROME HELICASE PROTEIN INHIBITORS | BREAKPOINT THERAPEUTICS GMBH (DE) | 2025-12-26 | — | — | WO | disclosed |
| CN-114269720-B | Acetyl-coa synthetase short chain2(ACSS2) Small molecule inhibitors of (a) | 库拉德夫制药私人有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-113801163-B | Organic arsenic-based II-type pyruvate kinase inhibitor and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2025-03-04 | — | — | CN | disclosed |
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2024-03-05 | — | — | US | disclosed |
| US-20230331707-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331707-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331707-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-10-19 | — | — | US | disclosed |
| CN-116514679-A | Palladium-catalyzed sp with low-cost and high-efficiency quaternary ammonium nitrate as oxidant 2 And sp (sp) 3 Carbon hydrogen bond alkenylation method | 南京工业大学 | 2023-08-01 | — | — | CN | disclosed |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2001055096-A1 | METHOD FOR PRODUCING N-ALKOXY-N-ALKYLAMIDES | LONZA AG (CH) | 2001-08-02 | — | — | WO | disclosed |
| EP-1091938-A2 | ANTIHISTAMINIC PIPERIDINE DERIVATIVES AND INTERMEDIATES FOR THE PREPARATION THEREOF | Aventis Pharmaceuticals Inc. (US) | 2001-04-18 | — | — | EP | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-2000001671-A2 | ANTIHISTAMINIC PIPERIDINE DERIVATIVES AND INTERMEDIATES FOR THE PREPARATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| US-5691356-A | ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-11-25 | — | — | US | disclosed |
| EP-0772601-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003387-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| EP-0388691-A1 | Azole-1-alkanamides as antiarrhytmic agents and preparation thereof | STERLING DRUG INC. (US) | 1990-09-26 | — | — | EP | disclosed |
| US-4925857-A | Pyridinyl-1H-pyrazole-1-alkanamides as antiarrhythmic agents | STERLING DRUG INC. (US) | 1990-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331707-A1 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | RIPK1, RIPK4, RIPK3 | ALOX5 2183/4885CES2 4869/4885CES1 2783/4885 |
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | ALOX5 1177/4885CES2 2739/4885CES1 820/4885 |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | ASNS, SI, NARS1 | ALOX5 1486/4885CES2 2523/4885CES1 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.